BridgeBio Pharma (BBIO)
(Real Time Quote from BATS)
$23.98 USD
+0.42 (1.78%)
Updated Jun 27, 2024 11:36 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
BridgeBio Pharma, Inc. [BBIO]
Reports for Purchase
Showing records 1 - 20 ( 34 total )
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Remains Compelling; Oncology Spinout; Modulating PT to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis European Rights Licensed to Bayer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Pipeline Advancing; 2023 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Infigratinib Partnered in Japan; TTR Amyloidosis Competition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Application Accepted for Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Notches Pivotal Trial Success in Japan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis FDA Decision in 4Q24; Pipeline Maturation; Raising PT to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Optimized Entry and Exit Levels for BBIO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
E.N.D.O - Exploring New Drug Opportunities in Endocrinology KOL Call Highlights
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Updated Acoramidis Data; Outlook Remains Speculative; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Novel Compounds to Treat ATTR Amyloidosis Appear on Track to Generate Peak Annual Revenues of $50B-Plus
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
BBP-418 Proof-of-Concept Data; NULIBRY Asset Sale; Adjusting PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Multiple Pipeline Catalysts Approaching; 2021 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Second Gene Therapy Candidate Enters Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Precision Oncology Collaboration With Amgen Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Phase 3 Trial Misses Primary Endpoint; Lowering PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Recent Approvals Validate Approach; R&D Day Showcase; Raising PT to $88
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Oncology Pipeline Appears Underrated; Raising PT to $87
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
The Bugs for Your Gut: Takeaways from the Recent Autism Spectrum Disorders Symposium
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A